{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:56:41Z","timestamp":1759453001956,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.blre.2022.100946","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T01:44:45Z","timestamp":1645407885000},"page":"100946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pitfalls in laboratory monitoring of treatment in people with Haemophilia"],"prefix":"10.1016","volume":"55","author":[{"given":"Will","family":"Lester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Reilly-Stitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.blre.2022.100946_bb0005","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/jth.13359","article-title":"Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX","volume":"14","author":"Ros\u00e9n","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.blre.2022.100946_bb0010","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jth.13348","article-title":"Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study","volume":"14","author":"Bowyer","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.blre.2022.100946_bb0015","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/hae.13168","article-title":"Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-Centre study","volume":"23","author":"Hillarp","year":"2017","journal-title":"Haemophilia."},{"issue":"2","key":"10.1016\/j.blre.2022.100946_bb0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.13215","article-title":"A critical appraisal of one-stage and chromogenic assays of factor VIII activity","volume":"14","author":"Peyvandi","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2022.100946_bb0025","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/hae.13907","article-title":"Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: a United Kingdom Haemophilia Centre Doctors\u2019 Organisation guideline","volume":"26","author":"Gray","year":"2020","journal-title":"Haemophilia."},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2022.100946_bb0030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/hae.12423","article-title":"Monitoring of modified factor VIII and IX products","volume":"20","author":"Kitchen","year":"2014","journal-title":"Haemophilia."},{"issue":"3","key":"10.1016\/j.blre.2022.100946_bb0040","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jth.13932","article-title":"International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories","volume":"16","author":"St Ledger","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.blre.2022.100946_bb0055","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"Collins","year":"2016","journal-title":"Haemophilia."},{"issue":"9","key":"10.1016\/j.blre.2022.100946_bb0060","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A Pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A","volume":"57","author":"Yoneyama","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.blre.2022.100946_bb0070","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia a treatments: new challenges","volume":"4","author":"Lenting","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.blre.2022.100946_bb0075","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2022.100946_bb0080","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/hae.13903","article-title":"Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors\u2019 Organisation guideline","volume":"26","author":"Jenkins","year":"2020","journal-title":"Haemophilia."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22000200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:27:20Z","timestamp":1759436840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22000200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":12,"alternative-id":["S0268960X22000200"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100946","relation":{},"ISSN":["0268-960X"],"issn-type":[{"type":"print","value":"0268-960X"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pitfalls in laboratory monitoring of treatment in people with Haemophilia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100946"}}